HT
Halozyme Therapeutics Inc.
HALO· Health Care· BiotechnologyS&P 400
Close · 26/10/2026
128.01
1D
+1.89%52-week range
61.23 – 128.11
Volume
12,37,300.00
Price history
HALO
25/09/2026 to 26/10/2026
O 126.03 H 128.11 L 126.03
1W+4.50%
1M+12.39%
3M+53.40%
6M+98.50%
1Y+91.37%
3Y+257.57%
5Y+244.95%
MAX+214.52%
Fundamentals
as of 26/10/2026- Market cap
- $14.53B
- Shares out
- 113.50M
- P/E (trailing)
- 35.13
- P/E (forward)
- 11.76
- EPS (trailing)
- 3.64
- Dividend yield
- 0.00%
- Beta
- 0.88
- Profit margin
- 24.86%
- P/B
- 101.22
- Return on equity
- 288.13%
SEC financial statements
59 quarterly and 17 annual periods through 30/06/2026.
Details
- Ticker
- HALO
- Index
- SP400
- Sector
- Health Care
- Industry
- Biotechnology
- HQ
- -
Last close 26/10/2026.
Tracked by Congress
3 filers · 1 on watchlist · 1 buy · 6 sells · ?: 1 · D: 6
- 29/09/2026Gilbert CisnerosSell+Halozyme Therapeutics, Inc. - Common Stock$1,001–$15,000
- 09/03/2026Gilbert CisnerosBuyHalozyme Therapeutics, Inc. - Common Stock$1,001–$15,000
- 24/03/2025Gilbert CisnerosSell+Halozyme Therapeutics, Inc. - Common Stock$1,001–$15,000
- 09/09/2024Josh GottheimerWSell+Halozyme Therapeutics, Inc. - Common Stock$1,001–$15,000
- 12/07/2023Daniel GoldmanSellHalozyme Therapeutics, Inc.$15,001–$50,000
- 06/12/2022Josh GottheimerWSell+Halozyme Therapeutics, Inc.$1,001–$15,000
- 05/08/2022Josh GottheimerWSell+Halozyme Therapeutics, Inc.$1,001–$15,000